Margaret K. Pasqule, PhD, Anthony M. Louder, PhD, RPh, Raymond Y. Cheung, PhD, Andrew T. Reiners, MD, Robert J. Sanchez, PhD, Veerainder Goli, MD, MBA, DFAPA, Jack Mardekian, PhD
From 1999 to 2008, the utilization rate of total knee replacement procedures in the United States more than doubled for the overall population, and tripled for individuals aged 45 to 64 years.
Knee and Hip Pain: Rewarding Optimal Long-Term Management
Janice M.S. Lopez, PharmD, MPH, Brian Macomson, PharmD, Varun Ektare, MPH, Dipen Patel, PhD, Marc Botteman, MSc
The Impact of HbA1c Testing on Total Annual Healthcare Expenditures Among Newly Diagnosed Patients with Diabetes
Treatment Sequences and Pharmacy Costs of 2 New Therapies for Metastatic Castration-Resistant Prostate Cancer
Lorie A. Ellis, PhD, Laurence Gozalo, PhD, Marie-Hélène Lafeuille, MA, Patrick Lefebvre, MA, Scott McKenzie, MD, Dominic Pilon, MA
Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework
Anuja Roy, PhD, MBA, Jonathan K. Kish, PhD, MPH, Lisa Bloudek, PharmD, MS, David S. Siegel, MD, PhD, Sundar Jagannath, MD, Denise Globe, PhD, Emil T. Kuriakose, MD, Kristen Migliaccio-Walle, BS
Multiple myeloma is a malignant B-cell neoplasm of terminally differentiated plasma cells that accumulate in the bone marrow and frequently invade the adjacent bone, leading to bone destruction and marrow failure.
The Rationale for Comparing the Costs of Competing Treatment Options in Oncology
Sally Amanuel, MSc, MA, MBA, Paola Antonini, MD, PhD, Victoria Coutinho, MSc, PhD, Thomas Goss, PharmD, Zhihong Lai, PhD, Sotiris Rompas, Phd, Michael F. Murphy, MD, PhD
Adherence to Insulin Pen Therapy Is Associated with Reduction in Healthcare Costs Among Patients with Type 2 Diabetes Mellitus
Machaon M. Bonafede, PhD, MPH, Arthi Chandran, MS, MPH, Laurence J Hirsch, MD, Betsy J Lahue, MPH, Sonali Nigam, MPH, Rita Saltiel-Berzin, RN, MPH, CDE, CHES
Shelby Corman, PharmD, MS, BCPS, Xin Gao, PhD, Sizhu Liu, MS, Reema Mody, PhD,MBA, Haridarshan Patel, PharmD, Yin Wan, MS, BSPharm
Opioid-induced constipation (OIC) can be a debilitating side effect of opioid therapy and may result in increased medical costs. The published data on the economic burden of OIC among long-term opioid users are limited.
Opioid-Induced Constipation Associated with Considerable Economic Burden
Gabriela Dieguez, FSA, MAAA, Amy W. Law, PharmD, Richard Lynen, MD, James Trussell, PhD, Bruce Pyenson, FSA, MAAA
Pregnancy is associated with a significant cost for employers providing health insurance benefits to their employees. The latest study on the topic was published in 2002, estimating the unintended pregnancy rate for women covered by employer-sponsored insurance benefits to be approximately 29%.
A Call to Action to Address Burden of Unintended Pregnancies in Plans’ Benefit Design
Budgetary Impact of Adding Riociguat to a US Health Plan for the Treatment of Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension
Chakkarin Burudpakdee, PharmD, Anshul Shah, MS, Vijay N Joish, PhD, Christine H. Divers, PhD, Avin Yaldo, PhD
Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), the 2 subtypes of pulmonary hypertension, are chronic, debilitating, and life-threatening conditions.
Is It Time for Risk-Sharing Contracts In Specialty Pharmacy?
Page 4 of 12
Results 31 - 40 of 114
Results 31 - 40 of 114